PerkinElmer uses cookies to ensure that we give you the best experience possible on our website. This may include cookies from third party websites. If you continue without changing your settings, we will assume that you consent to receive cookies from this website. You can change your cookie settings at any time. To learn more, please review our cookie policy, which includes information on how to manage your cookies.

Life Sciences

From basic research and drug discovery to the development and manufacturing of new, significant drugs and clinical treatments, we are helping researchers accelerate the discovery-to-commercialization process, bringing better medicines to market faster. With a comprehensive portfolio from detection and imaging solutions to informatics and services, our forward-minded ideation to advance research possibilities have enabled many methods that once took weeks to perform to now be accomplished in a matter of hours.

Areas of Interest

Disease Research

PerkinElmer’s portfolio provides disease researchers the tools that enable insights and interactions between cell types and organ systems that lead to breakthroughs in prevention, early detection and treatment of diseases.

Learn More

Pharmaceuticals

The discovery and development of small-molecule drugs is a long, complex, often iterative, and expensive journey. Each step of the process, from early discovery through to manufacturing and delivery, must be fully explored, characterized, and understood. Speed to market, decline in productivity and low success rate are regarded as major industry challenges in Drug Discovery.

Biologics

From discovery through manufacturing, harnessing large molecule drugs to create safe and effective therapies is complex and expensive. PerkinElmer enables scientists to develop and streamline their entire biologics workflow so they can overcome these challenges and bring consistent, high-quality, biological medicines to market faster.

Learn More

Stories

Tackling Tumor Resistance

The ability of tumors to evolve drug resistance is a major challenge in oncology research. Read how new insights could help researchers tackle this to make more effective treatments.

Repurpose, Reuse, Rediscover Drugs for COVID-19 Treatments

When a research team at the NCATS, an institute within the NIH, was tasked to help find a possible COVID-19 therapeutic, they decided on a drug repurposing strategy.

Improving Drug Safety Through Cardiotoxicity Assessment

A top reason for drug withdrawal from clinical trials and the market is cardiotoxicity. Learn how technology can help identity these adverse effects earlier in drug development.

Supporting Your Journey

Developing new medicines is a long and complex journey that starts with understanding the biology of a disease and then treating it. We understand those challenges and support you throughout your journey.